Loss of cell-surface laminin anchoring promotes tumor growth and is associated with poor clinical outcomes

Cancer Research

Volumn 72, Issue 10, 2012, Pages 2578-2588

  Akhavan, Armin ^a   Griffith, Obi L ^b   Soroceanu, Liliana ^a   Leonoudakis, Dmitri ^a   Luciani Torres, Maria Gloria ^a   Daemen, Anneleen ^b   Gray, Joe W ^b,c,d   Muschler, John L ^a,c  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c Oregon Health and Science University Department of Biomedical Engineering   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROGLYCAN; GLYCOSYLTRANSFERASE; LAMININ; LIKE ACETYLGLUCOSAMINYLTRANSFERASE; N ACETYLGLUCOSAMINYLTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER SURVIVAL; CELL ADHESION; CELL FUNCTION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLYCOSYLATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; DISEASE PROGRESSION; DYSTROGLYCANS; EXTRACELLULAR MATRIX; GLYCOSYLATION; HUMANS; LAMININ; N-ACETYLGLUCOSAMINYLTRANSFERASES; NEOPLASMS;

EID: 84861137691     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3732     Document Type: Article

References (49)

1. Hu M, Polyak K. Microenvironmental regulation of cancer development. Curr Opin Genet Dev 2008;18:27-34. (Pubitemid 351694443)
2. Anderson AR, Weaver AM, Cummings PT, Quaranta V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 2006; 127:905-15. (Pubitemid 44792251)
3. Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009;461: 109-13.
4. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009;139:891-906.
5. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74. (Pubitemid 37328786)
6. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001;1:46-54. (Pubitemid 33741880)
7. Yurchenco PD, Patton BL. Developmental and pathogenic mechanisms of basement membrane assembly. Curr Pharm Des 2009;15: 1277-94.
8. Kadler KE, Hill A, Canty-Laird EG. Collagen fibrillogenesis: fibronectin, integrins, and minor collagens as organizers and nucleators. Curr Opin Cell Biol 2008;20:495-501.
9. Sasaki T, Fassler R, Hohenester E. Laminin: the crux of basement membrane assembly. J Cell Biol 2004;164:959-63. (Pubitemid 38429121)
10. Colognato H, Winkelmann DA, Yurchenco PD. Laminin polymerization induces a receptor-cytoskeleton network. J Cell Biol 1999;145: 619-31. (Pubitemid 29215724)
11. Lohikangas L, Gullberg D, Johansson S. Assembly of laminin polymers is dependent on beta1-integrins. Exp Cell Res 2001;265:135-44. (Pubitemid 32989071)
12. Henry MD, Campbell KP. A role for dystroglycan in basement membrane assembly. Cell 1998;95:859-70. (Pubitemid 29014465)
13. Weir ML, Oppizzi ML, Henry MD, Onishi A, Campbell KP, Bissell MJ, et al. Dystroglycan loss disrupts polarity and {beta}-casein induction in mammary epithelial cells by perturbing laminin anchoring. J Cell Sci 2006;119:4047-58. (Pubitemid 44650877)
14. Li S, Liquari P, McKee KK, Harrison D, Patel R, Lee S, et al. Lamininsulfatide binding initiates basement membrane assembly and enables receptor signaling in Schwann cells and fibroblasts. J Cell Biol 2005;169:179-89. (Pubitemid 40562924)
15. Streuli CH, Schmidhauser C, Bailey N, Yurchenco P, Skubitz AP, Roskelley C, et al. Laminin mediates tissue-specific gene expression in mammary epithelia. J Cell Biol 1995;129:591-603.
16. Patarroyo M, Tryggvason K, Virtanen I. Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin Cancer Biol 2002;12: 197-207. (Pubitemid 34833063)
17. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW. The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation 2002;70:537-46. (Pubitemid 36194318)
18. Gudjonsson T, Ronnov-Jessen L, Villadsen R, Rank F, Bissell MJ, Petersen OW. Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. J Cell Sci 2002; 115:39-50. (Pubitemid 34105527)
19. Yang XH, Flores LM, Li Q, Zhou P, Xu F, Krop IE, et al. Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res 2010;70: 2256-63.
20. Weaver VM, Lelievre S, Lakins JN, Chrenek MA, Jones JC, Giancotti F, et al. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2002;2:205-16. (Pubitemid 41043976)
21. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27. (Pubitemid 44854747)
22. Lee Y, Kameya S, Cox GA, Hsu J, Hicks W, Maddatu TP, et al. Ocular abnormalities in Large(myd) and Large(vls) mice, spontaneous models for muscle, eye, and brain diseases. Mol Cell Neurosci 2005;30: 160-72. (Pubitemid 41316560)
23. Mortazavi A, WilliamsBA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008;5:621-8. (Pubitemid 351911867)
24. Griffith M, Griffith OL, Mwenifumbo J, Goya R, Morrissy AS, Morin RD, et al. Alternative expression analysis byRNAsequencing. Nat Methods 2010;7:843-7.
25. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7.
26. Leonoudakis D, Singh M, Mohajer R, Mohajer P, Fata JE, Campbell KP, et al. Dystroglycan controls signaling of multiple hormones through modulation of STAT5 activity. J Cell Sci 2010;123: 3683-92.
27. Henry MD, Satz JS, Brakebusch C, Costell M, Gustafsson E, Fassler R, et al. Distinct roles for dystroglycan, (b)1 integrin and perlecan in cell surface laminin organization. J Cell Sci 2001;114: 1137-44. (Pubitemid 32288527)
28. Heiser LM, Wang NJ, Talcott CL, Laderoute KR, Knapp M, Guan Y, et al. Integrated analysis of breast cancer cell lines reveals unique signaling pathways. Genome Biol 2009;10:R31.
29. Barresi R, Campbell KP. Dystroglycan: from biosynthesis to pathogenesis of human disease. J Cell Sci 2006;119:199-207. (Pubitemid 43210689)
30. Martin LT, Glass M, Dosunmu E, Martin PT. Altered expression of natively glycosylated alpha dystroglycan in pediatric solid tumors. Hum Pathol 2007;38:1657-68. (Pubitemid 47589088)
31. Bao X, Kobayashi M, Hatakeyama S, Angata K, Gullberg D, Nakayama J, et al. Tumor suppressor function of lamininbinding alpha-dystroglycan requires a distinct beta3-N-acetylglucosaminyltransferase. Proc Natl Acad Sci U S A 2009;106: 12109-14.
32. Beltran-Valero de Bernabe D, Inamori KI, Yoshida-Moriguchi T, Weydert CJ, Harper HA, Willer T, et al. Loss of alpha-dystroglycan laminin binding in epithelium-derived cancers is caused by silencing of large. J Biol Chem 2009;284:11279-84.
33. Singh J, Itahana Y, Knight-Krajewski S, Kanagawa M, Campbell KP, Bissell MJ, et al. Proteolytic enzymes and altered glycosylation modulate dystroglycan function in carcinoma cells. Cancer Res 2004;64: 6152-9. (Pubitemid 39129416)
34. Hewitt JE. Abnormal glycosylation of dystroglycan in human genetic disease. Biochim Biophys Acta 2009;1792:853-61.
35. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008;26:2568-81.
36. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006;24:778-89. (Pubitemid 46622045)
37. Kaiser S, Park YK, Franklin JL, Halberg RB, Yu M, Jessen WJ, et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol 2007;8:R131.
38. Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, et al. Patterns of gene expression and copy-number alterations in von- Hippel Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009;69:4674-81.
39. Vanaja DK, Cheville JC, Iturria SJ, Young CY. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003;63: 3877-82. (Pubitemid 36917897)
40. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 2008;1:13.
41. Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006;9:287-300.
42. Ginos MA, Page GP, Michalowicz BS, Patel KJ, Volker SE, Pambuccian SE, et al. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 2004;64:55-63. (Pubitemid 38114082)
43. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73. (Pubitemid 43357943)
44. Godfrey C, Foley AR, Clement E, Muntoni F. Dystroglycanopathies: coming into focus. Curr Opin Genet Dev 2011;21:278-85.
45. van Reeuwijk J, Grewal PK, Salih MA, Beltran-Valero de Bernabe D, McLaughlan JM, Michielse CB, et al. Intragenic deletion in the LARGE gene causes Walker-Warburg syndrome. Hum Genet 2007; 121:685-90.
46. Huang L, Muthuswamy SK. Polarity protein alterations in carcinoma: a focus on emerging roles for polarity regulators. Curr Opin Genet Dev 2010;20:41-50.
47. Peyrard M, Seroussi E, Sandberg-Nordqvist AC, Xie YG, Han FY, Fransson I, et al. The human LARGE gene from 22q12.3-q13.1 is a new, distinct member of the glycosyltransferase gene family. Proc Natl Acad Sci U S A 1999;96: 598-603. (Pubitemid 29061254)
48. Fackler MJ, Umbricht C, Williams D, Argani P, Cruz LA, Merino VF, et al. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res 2011;71:6195-207.
49. Petersen OW, Ronnov JL, Howlett AR, Bissell MJ. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci U S A 1992;89:9064-8.